Abstract: Background: Postpartum Haemorrhage (PPH) is one of the leading causes of maternal mortality claiming upto 700,000 lives globally each year. WHO recommends early use of intravenous Tranexamic acid as soon as possible after diagnosis of PPH (preferably within 3 hours of birth) for women with presenting PPH after vaginal birth or caesarean section.
Objective: To evaluate the efficacy and safety of intravenous Tranexamic acid (TXA) for preventing PPH after vaginal and caesarean births and to record any adverse effects following its administration.
Materials and Methods: This study was conducted as a randomized, double-blind, placebo controlled trial on patients at risk for PPH who delivered vaginally or by caesarean section at our institute. The participants were randomly categorized into two groups study group (receiving tranexamic acid) and control group. The two groups were compared with respect to effectiveness (volume of blood loss and incidence of PPH) and safety (vitals and adverse drug reactions).
Results: Average blood loss measured from the delivery of placenta till 2 hours post-partum was significantly lower in study group as compared to control group (p<0.05). Incidence of PPH was significantly higher in control group (p<0.05). There was no statistically difference in the vitals recorded immediately post- partum and after 2 hours between two groups (p>0.05). There was no incidence of any adverse drug reaction reported in the study group.
Conclusion: Tranexamic acid can be used safely and effectively for prophylactic management of PPH regardless of the mode of delivery. Tranexamic acid was not associated with major complications or maternal or perinatal mortality and morbidity.
Indexed in Index Copernicus
